Cytokinetics Inc (CYTK)
54.70
-1.26
(-2.25%)
USD |
NASDAQ |
Nov 14, 16:00
54.71
+0.01
(+0.02%)
After-Hours: 20:00
Cytokinetics Cash from Investing (Quarterly): -45.05M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -45.05M |
| June 30, 2024 | -651.55M |
| March 31, 2024 | 32.64M |
| December 31, 2023 | -81.41M |
| September 30, 2023 | 73.04M |
| June 30, 2023 | 82.13M |
| March 31, 2023 | 165.50M |
| December 31, 2022 | 29.25M |
| September 30, 2022 | -292.37M |
| June 30, 2022 | 65.27M |
| March 31, 2022 | -64.28M |
| December 31, 2021 | 47.34M |
| September 30, 2021 | -208.72M |
| June 30, 2021 | 18.88M |
| March 31, 2021 | -5.276M |
| December 31, 2020 | -173.62M |
| September 30, 2020 | -101.02M |
| June 30, 2020 | 34.64M |
| March 31, 2020 | 43.49M |
| December 31, 2019 | -105.27M |
| September 30, 2019 | 13.68M |
| June 30, 2019 | -2.767M |
| March 31, 2019 | 19.64M |
| December 31, 2018 | 26.51M |
| September 30, 2018 | 2.677M |
| Date | Value |
|---|---|
| June 30, 2018 | -44.19M |
| March 31, 2018 | 20.14M |
| December 31, 2017 | 30.76M |
| September 30, 2017 | 39.66M |
| June 30, 2017 | -23.95M |
| March 31, 2017 | -112.30M |
| December 31, 2016 | -41.97M |
| September 30, 2016 | 13.97M |
| June 30, 2016 | -3.916M |
| March 31, 2016 | -20.16M |
| December 31, 2015 | 25.41M |
| September 30, 2015 | 11.31M |
| June 30, 2015 | 11.44M |
| March 31, 2015 | -32.09M |
| December 31, 2014 | 6.304M |
| September 30, 2014 | 10.07M |
| June 30, 2014 | 8.44M |
| March 31, 2014 | -28.86M |
| December 31, 2013 | 5.813M |
| September 30, 2013 | -7.592M |
| June 30, 2013 | -10.21M |
| March 31, 2013 | 10.47M |
| December 31, 2012 | 6.616M |
| September 30, 2012 | -38.97M |
| June 30, 2012 | -1.509M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-651.55M
Minimum
Jun 2024
165.50M
Maximum
Mar 2023
-56.82M
Average
6.802M
Median
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -30.25M |
| Biomarin Pharmaceutical Inc | -16.16M |
| Catalyst Pharmaceuticals Inc | -0.259M |
| Sarepta Therapeutics Inc | -128.82M |
| Ocugen Inc | -0.513M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -101.50M |
| Cash from Financing (Quarterly) | 3.425M |
| Free Cash Flow | -407.05M |
| Free Cash Flow Per Share (Quarterly) | -0.8684 |
| Free Cash Flow to Equity (Quarterly) | -103.27M |
| Free Cash Flow Yield | -6.96% |